Trial Profile
A 16-Week, Multicenter, Randomized, Open-Label Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 29 Dec 2021
Price :
$35
*
At a glance
- Drugs Aripiprazole (Primary) ; Olanzapine; Quetiapine; Risperidone
- Indications Schizophrenia
- Focus Pharmacodynamics
- Sponsors Bristol-Myers Squibb
- 30 Sep 2021 This trial has been completed in France (End Date: 17 Mar 2009), according to European Clinical Trials Database record.
- 28 Apr 2012 Planned number of patients changed from 258 to 860 as reported by European Clinical Trials Database record.
- 21 Oct 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.